Raleigh, NC, United States of America

Cheng-Wen Lin

USPTO Granted Patents = 15 

 

Average Co-Inventor Count = 3.9

ph-index = 7

Forward Citations = 111(Granted Patents)


Location History:

  • Durham, NC (US) (2014 - 2020)
  • Raleigh, NC (US) (2016 - 2023)

Company Filing History:


Years Active: 2014-2023

Loading Chart...
Loading Chart...
15 patents (USPTO):

Title: Innovations of Cheng-Wen Lin

Introduction

Cheng-Wen Lin is a prominent inventor based in Raleigh, NC, known for his significant contributions to the field of ophthalmic compositions. With a total of 15 patents to his name, Lin has made remarkable advancements that have the potential to enhance eye care and treatment.

Latest Patents

Among his latest patents, Lin has developed ophthalmic compositions that include 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts. These compositions also contain about 0.01% weight/volume to about 1.0% weight/volume of a buffer and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent. His innovative approach in this area showcases his commitment to improving ophthalmic solutions.

Career Highlights

Throughout his career, Cheng-Wen Lin has worked with notable companies such as Aerie Pharmaceuticals, Inc. and Novaer Holdings, Inc. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research and development in ophthalmology.

Collaborations

Lin has collaborated with talented individuals in his field, including Casey Kopczynski and Jill Marie Sturdivant. These partnerships have fostered an environment of innovation and creativity, leading to the development of impactful inventions.

Conclusion

Cheng-Wen Lin's work in ophthalmic compositions exemplifies the spirit of innovation in the medical field. His patents and collaborations highlight his dedication to advancing eye care solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…